



Friday, July 10, 2020 | 09:00 - 10:00 (CEST)

- Acute myeloid leukemia: AML from target to residual disease
- Bleeding and thrombosis: Understanding thrombosis and bleeding risk in patients with hematological malignancies
- ELN-EHA SWG for CML: CML - What is new?
- European Scientific Foundation for Laboratory Hemato Oncology (ELSHO): New developments in NGS-based immunogenetics
- Genetic predisposition hematologic cancer: Genetic predisposition for lymphoid leukemia: Genetics and clinical implications
- Immune therapies for hematologic disorders
- Lymphoma: Treating follicular lymphoma in 2020
- Myeloproliferative neoplasms (MPN): Understanding the latest data in MPN and using social media to share knowledge
- Precision hematology: Functional precision hematology
- Stem cells: Emergence of hematopoietic stem cells (HSC) during development
- Transfusion: Red cell transfusion: The past, the present, and the future
- Aging and hematology: Cardiac toxicity in older adults with hematologic malignancies
- Diagnosis in hematological diseases: Morphological and immunophenotypic diagnosis in non-malignant hematological diseases
- European Research Initiative on CLL (ERIC)
- European Working Group on Adult ALL (EWALL)
- Granulocytes & constitutional marrow failure disorders: Marrow failure and predisposition to leukemia
- Infections in hematology: When modern hematology and current standards meet at CYP450
- Mesenchymal stem cells (MSC): MSC, friends and foes
- Myelodysplastic syndromes (MDS): Allogeneic Tx for elderly MDS/AML in the era of novel therapies
- Red cell and iron: Advances in hemoglobinopathies
- Thrombocytopenias and platelet function disorders: Thrombocytopenias: New approaches to old problems
- Quality of life and symptoms: Advances in the use of PRO in hematology